{"title":"The Basics of Neonatal Hyperbilirubinemia.","authors":"Megan Falke","doi":"10.1891/NN-2024-0051","DOIUrl":null,"url":null,"abstract":"<p><p>Neonatal jaundice is a common condition affecting four out of five healthy newborns, characterized by the yellowing of the skin due to elevated bilirubin levels. This condition, known as hyperbilirubinemia, is typically benign and transient when properly managed but may progress to severe complications such as kernicterus-a permanent neurologic condition-if untreated. Newborns are particularly susceptible to jaundice due to increased red blood cell turnover, immature liver enzymes, and delayed stooling patterns. Preventive measures during pregnancy, such as maternal blood typing and Rh immunoglobulin administration, can mitigate the risk of hemolytic conditions leading to jaundice. Early detection through bilirubin screening and prompt treatment, including phototherapy, are critical to preventing neurotoxicity. Recent updates to the American Academy of Pediatrics guidelines emphasize higher thresholds for intervention, stratified by gestational age and risk factors. Effective management relies on thorough assessment, parental education, and close postdischarge follow-up. Understanding the pathophysiology, risk factors, and treatment protocols enables health care providers to optimize outcomes and prevent long-term sequelae in affected infants. This article will provide an overview of neonatal jaundice and neonatal hyperbilirubinemia, focusing on its pathophysiology, diagnostic methods, and the most recent treatment guidelines. The aim is to provide this guidance to support the bedside NICU nursing practice.</p>","PeriodicalId":46706,"journal":{"name":"Neonatal Network","volume":"44 1","pages":"61-67"},"PeriodicalIF":0.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neonatal Network","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1891/NN-2024-0051","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NURSING","Score":null,"Total":0}
引用次数: 0
Abstract
Neonatal jaundice is a common condition affecting four out of five healthy newborns, characterized by the yellowing of the skin due to elevated bilirubin levels. This condition, known as hyperbilirubinemia, is typically benign and transient when properly managed but may progress to severe complications such as kernicterus-a permanent neurologic condition-if untreated. Newborns are particularly susceptible to jaundice due to increased red blood cell turnover, immature liver enzymes, and delayed stooling patterns. Preventive measures during pregnancy, such as maternal blood typing and Rh immunoglobulin administration, can mitigate the risk of hemolytic conditions leading to jaundice. Early detection through bilirubin screening and prompt treatment, including phototherapy, are critical to preventing neurotoxicity. Recent updates to the American Academy of Pediatrics guidelines emphasize higher thresholds for intervention, stratified by gestational age and risk factors. Effective management relies on thorough assessment, parental education, and close postdischarge follow-up. Understanding the pathophysiology, risk factors, and treatment protocols enables health care providers to optimize outcomes and prevent long-term sequelae in affected infants. This article will provide an overview of neonatal jaundice and neonatal hyperbilirubinemia, focusing on its pathophysiology, diagnostic methods, and the most recent treatment guidelines. The aim is to provide this guidance to support the bedside NICU nursing practice.